Wang K, Ojeda N, Wang H, Chiang H, Tucci M, Lee J
Neurochem Int. 2024; 176:105743.
PMID: 38641026
PMC: 11102812.
DOI: 10.1016/j.neuint.2024.105743.
Wu M, Su H, Zhao M
Neurotox Res. 2021; 39(3):1007-1021.
PMID: 33555547
DOI: 10.1007/s12640-021-00332-2.
Fultz E, Quadir S, Martin D, Flaherty D, Worley P, Kippin T
Int J Mol Sci. 2021; 22(3).
PMID: 33540617
PMC: 7867251.
DOI: 10.3390/ijms22031473.
Pantoni M, Anagnostaras S
Pharmacol Rev. 2019; 71(3):413-449.
PMID: 31249067
PMC: 6607799.
DOI: 10.1124/pr.118.017087.
Tserovski S, Georgieva S, Bogdanova D, Matev B
J Surg Case Rep. 2019; 2019(1):rjy366.
PMID: 30740204
PMC: 6354760.
DOI: 10.1093/jscr/rjy366.
Corticosterone and exogenous glucose alter blood glucose levels, neurotoxicity, and vascular toxicity produced by methamphetamine.
Bowyer J, Tranter K, Sarkar S, George N, Hanig J, Kelly K
J Neurochem. 2017; 143(2):198-213.
PMID: 28792619
PMC: 5763366.
DOI: 10.1111/jnc.14143.
Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.
Schrantee A, Tremoleda J, Wylezinska-Arridge M, Bouet V, Hesseling P, Meerhoff G
PLoS One. 2017; 12(2):e0172776.
PMID: 28241065
PMC: 5328278.
DOI: 10.1371/journal.pone.0172776.
MDMA decreases glutamic acid decarboxylase (GAD) 67-immunoreactive neurons in the hippocampus and increases seizure susceptibility: Role for glutamate.
Huff C, Morano R, Herman J, Yamamoto B, Gudelsky G
Neurotoxicology. 2016; 57:282-290.
PMID: 27773601
PMC: 5123907.
DOI: 10.1016/j.neuro.2016.10.011.
Signaling Mechanisms in the Nitric Oxide Donor- and Amphetamine-Induced Dopamine Release in Mesencephalic Primary Cultured Neurons.
Salum C, Schmidt F, Michel P, Del-Bel E, Raisman-Vozari R
Neurotox Res. 2015; 29(1):92-104.
PMID: 26391887
DOI: 10.1007/s12640-015-9562-8.
Legal highs: staying on top of the flood of novel psychoactive substances.
Baumeister D, Tojo L, Tracy D
Ther Adv Psychopharmacol. 2015; 5(2):97-132.
PMID: 26240749
PMC: 4521440.
DOI: 10.1177/2045125314559539.
Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls.
Schrantee A, Ferguson B, Stoffers D, Booij J, Rombouts S, Reneman L
Brain Imaging Behav. 2015; 10(2):548-58.
PMID: 26149196
PMC: 4908160.
DOI: 10.1007/s11682-015-9419-z.
Dopaminergic system dysfunction in recreational dexamphetamine users.
Schrantee A, Vaclavu L, Heijtel D, Caan M, Gsell W, Lucassen P
Neuropsychopharmacology. 2014; 40(5):1172-80.
PMID: 25394786
PMC: 4367461.
DOI: 10.1038/npp.2014.301.
Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI.
Rouine J, Kelly M, Jennings-Murphy C, Duffy P, Gorman I, Gormley S
Psychopharmacology (Berl). 2014; 232(9):1501-13.
PMID: 25366875
DOI: 10.1007/s00213-014-3790-0.
Functional and structural brain changes associated with methamphetamine abuse.
Jan R, Kydd R, Russell B
Brain Sci. 2014; 2(4):434-82.
PMID: 24961256
PMC: 4061807.
DOI: 10.3390/brainsci2040434.
Mesocorticolimbic monoamine correlates of methamphetamine sensitization and motivation.
Lominac K, McKenna C, Schwartz L, Ruiz P, Wroten M, Miller B
Front Syst Neurosci. 2014; 8():70.
PMID: 24847220
PMC: 4019853.
DOI: 10.3389/fnsys.2014.00070.
Alterations to global but not local motion processing in long-term ecstasy (MDMA) users.
White C, Brown J, Edwards M
Psychopharmacology (Berl). 2014; 231(13):2611-22.
PMID: 24441968
DOI: 10.1007/s00213-014-3431-7.
Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile.
Mueller M, Maldonado-Adrian C, Yuan J, McCann U, Ricaurte G
J Pharmacol Exp Ther. 2012; 344(2):479-88.
PMID: 23209329
PMC: 3558829.
DOI: 10.1124/jpet.112.201699.
Effects of maternal separation and methamphetamine exposure on protein expression in the nucleus accumbens shell and core.
Dimatelis J, Russell V, Stein D, Daniels W
Metab Brain Dis. 2012; 27(3):363-75.
PMID: 22451087
DOI: 10.1007/s11011-012-9295-9.
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
Colfax G, Santos G, Das M, Santos D, Matheson T, Gasper J
Arch Gen Psychiatry. 2011; 68(11):1168-75.
PMID: 22065532
PMC: 3437988.
DOI: 10.1001/archgenpsychiatry.2011.124.
Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.
Morrow B, Roth R, Redmond D, Elsworth J
Neuroscience. 2011; 189:277-85.
PMID: 21640165
PMC: 3150352.
DOI: 10.1016/j.neuroscience.2011.05.046.